Genprex Inc. recently regained compliance with the Nasdaq minimum stockholders' equity requirement of $2.5 million, following a prior notice of deficiency in August 2025. The company will now be subject to a one-year mandatory monitoring period by Nasdaq through January 2027. If Genprex falls out of compliance with the equity requirement during this period, it will not be granted a cure period or allowed to submit a new compliance plan, and Nasdaq staff will issue a Delist Determination Letter. Genprex would then have the opportunity to request a hearing, but its securities could be delisted from Nasdaq.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-000995), on January 09, 2026, and is solely responsible for the information contained therein.